Biotech Roundup: Deals Gone Wrong, Ethical Red Flags & Bay Goodbyes
Xconomy
JUNE 3, 2016
The only remaining daptomycin patent will expire in June, clearing the way for generic competition years earlier than expected. A company official told Xconomy the drug would be priced in line with standard of care enzyme replacement therapy, which costs around $300,000 per patient, per year.
Let's personalize your content